Literature DB >> 11850165

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.

J M Bell1, J D Turnidge, R N Jones.   

Abstract

From 1998 to 1999, a large number of community-acquired respiratory tract isolates of Streptococcus pneumoniae (n=566), Haemophilus influenzae (n=513) and Moraxella catarrhalis (n=228) were collected from 15 centres in Australia, Hong Kong, Japan, China, the Philippines, Singapore, South Africa and Taiwan through the SENTRY Antimicrobial Surveillance Program. Isolates were tested against 26 antimicrobial agents using the NCCLS-recommended methods. Overall, 40% of S. pneumoniae isolates were resistant to penicillin with 18% of strains having high-level resistance (MIC > or =2 mg/l). Rates of erythromycin and clindamycin resistance were 41 and 23%, respectively. Penicillin-resistant strains showed high rates of resistance to other antimicrobial agents: 96% to trimethoprim-sulphamethoxazole (TMP-SMX), 84% to tetracycline and 81% to erythromycin. A significant proportion of penicillin-susceptible strains was also resistant to erythromycin (21%), tetracycline (29%) and TMP-SMZ (26%). Small numbers of strains were resistant to levofloxacin (0.7%), trovafloxacin (0.4%) and grepafloxacin (1.3%) where as all strains remained uniformly susceptible to quinupristin/dalfopristin and BMS284756 (MIC(90), 0.06 mg/l), a new desfluoroquinolone. beta-lactamases were, produced by 20% H. influenzae isolates and only rare strains showed intrinsic resistance to amoxycillin. Other beta-lactam agents showed good activity with rates of resistance less than 2% and all isolates showed susceptibility to cefixime, ceftibuten, cefepime and cefotaxime. Rates of resistance to tetracycline and chloramphenicol were also relatively low at 3%. The majority (98%) of M. catarrhalis isolates was found to be beta-lactamase-positive and resistant to penicillins, however, resistance to erythromycin and tetracycline was also low at 1.8%. Both H. influenzae and M. catarrhalis isolates were uniformly susceptible to the new desfluoroquinolone and tested fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850165     DOI: 10.1016/s0924-8579(01)00475-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  High prevalence of antimicrobial resistance among common bacterial isolates in a tertiary healthcare facility in Rwanda.

Authors:  Cyprien Ntirenganya; Olivier Manzi; Claude Mambo Muvunyi; Onyema Ogbuagu
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

2.  Molecular epidemiology of penicillin-susceptible non-beta-lactam-resistant Streptococcus pneumoniae isolates from Greek children.

Authors:  D Bogaert; P W M Hermans; I N Grivea; G S Katopodis; T J Mitchell; M Sluijter; R De Groot; N G Beratis; G A Syrogiannopoulos
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.

Authors:  J Barth; H Landen
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

4.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

5.  Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice : results of a post-marketing surveillance study.

Authors:  W Elies; H Landen; K Stauch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

6.  Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice : evidence from a post-marketing surveillance study of 1467 patients.

Authors:  H Koch; H Landen; K Stauch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

7.  Designing antibiotic cycling strategies by determining and understanding local adaptive landscapes.

Authors:  Christiane P Goulart; Mentar Mahmudi; Kristina A Crona; Stephen D Jacobs; Marcelo Kallmann; Barry G Hall; Devin C Greene; Miriam Barlow
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 8.  Bronchiectasis in Children: Current Concepts in Immunology and Microbiology.

Authors:  Susan J Pizzutto; Kim M Hare; John W Upham
Journal:  Front Pediatr       Date:  2017-05-29       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.